膜翅目毒液免疫治疗对临床过程、免疫参数和心理社会方面的长期影响。

Allergologie Select Pub Date : 2021-01-26 eCollection Date: 2021-01-01 DOI:10.5414/ALX02175E
Jan Adelmeyer, Julia Pickert, Wolfgang Pfützner, Christian Möbs
{"title":"膜翅目毒液免疫治疗对临床过程、免疫参数和心理社会方面的长期影响。","authors":"Jan Adelmeyer,&nbsp;Julia Pickert,&nbsp;Wolfgang Pfützner,&nbsp;Christian Möbs","doi":"10.5414/ALX02175E","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Venom immunotherapy (VIT) is highly efficient in subjects suffering from IgE-mediated allergy to hymenoptera venom (HV), and VIT results in substantial improvement of quality of life (QoL). However, VIT-induced tolerance may be lost over time after cessation of treatment, putting patients at risk of re-sting anaphylaxis.</p><p><strong>Materials and methods: </strong>To study the effect of VIT on maintenance of HV tolerance we evaluated the natural history of 54 patients who were treated with VIT up to 29 years ago, with a special focus on re-stings and their subsequent course. Furthermore, we analyzed HV-specific IgE, IgG, and IgG4 antibody titers. Finally, we assessed the long-term impact of VIT on various psychosocial aspects like dealing with hymenoptera exposures, daily life activities, self-assurance, and personal environment.</p><p><strong>Results: </strong>29 (53.7%) subjects experienced at least one re-sting after stopping VIT, with 23 (79%) showing no systemic reaction (SR). Eleven of these (37.9%) took emergency drugs as a safety measurement. Six individuals (21%) showed loss of tolerance experiencing an anaphylactic reaction. No difference in HV-specific IgE, IgG4, or IgG antibody concentrations was noticed among the different patients. Subjects who tolerated a re-sting without applying emergency drugs felt least affected in their social-behavioral leisure activities when hymenoptera were around or by anxiety for new stings.</p><p><strong>Conclusion: </strong>VIT leads to long-term tolerance in the majority of HV-allergic patients, however, ~ 1/5 may lose protection over time, arguing for continued follow-up on VIT-treated subjects and keeping them equipped with an emergency kit. Notably, VIT also results in a lasting, strong impact on self-assurance and sense of well-being in individuals who tolerated a re-sting without employing emergency drugs, which emphasizes the need to use them only in case of systemic symptoms after stopping successful VIT.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"5 ","pages":"57-66"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841418/pdf/","citationCount":"7","resultStr":"{\"title\":\"Long-term impact of hymenoptera venom immunotherapy on clinical course, immune parameters, and psychosocial aspects.\",\"authors\":\"Jan Adelmeyer,&nbsp;Julia Pickert,&nbsp;Wolfgang Pfützner,&nbsp;Christian Möbs\",\"doi\":\"10.5414/ALX02175E\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Venom immunotherapy (VIT) is highly efficient in subjects suffering from IgE-mediated allergy to hymenoptera venom (HV), and VIT results in substantial improvement of quality of life (QoL). However, VIT-induced tolerance may be lost over time after cessation of treatment, putting patients at risk of re-sting anaphylaxis.</p><p><strong>Materials and methods: </strong>To study the effect of VIT on maintenance of HV tolerance we evaluated the natural history of 54 patients who were treated with VIT up to 29 years ago, with a special focus on re-stings and their subsequent course. Furthermore, we analyzed HV-specific IgE, IgG, and IgG4 antibody titers. Finally, we assessed the long-term impact of VIT on various psychosocial aspects like dealing with hymenoptera exposures, daily life activities, self-assurance, and personal environment.</p><p><strong>Results: </strong>29 (53.7%) subjects experienced at least one re-sting after stopping VIT, with 23 (79%) showing no systemic reaction (SR). Eleven of these (37.9%) took emergency drugs as a safety measurement. Six individuals (21%) showed loss of tolerance experiencing an anaphylactic reaction. No difference in HV-specific IgE, IgG4, or IgG antibody concentrations was noticed among the different patients. Subjects who tolerated a re-sting without applying emergency drugs felt least affected in their social-behavioral leisure activities when hymenoptera were around or by anxiety for new stings.</p><p><strong>Conclusion: </strong>VIT leads to long-term tolerance in the majority of HV-allergic patients, however, ~ 1/5 may lose protection over time, arguing for continued follow-up on VIT-treated subjects and keeping them equipped with an emergency kit. Notably, VIT also results in a lasting, strong impact on self-assurance and sense of well-being in individuals who tolerated a re-sting without employing emergency drugs, which emphasizes the need to use them only in case of systemic symptoms after stopping successful VIT.</p>\",\"PeriodicalId\":7485,\"journal\":{\"name\":\"Allergologie Select\",\"volume\":\"5 \",\"pages\":\"57-66\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841418/pdf/\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergologie Select\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5414/ALX02175E\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologie Select","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5414/ALX02175E","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

摘要

背景:血清免疫疗法(VIT)对膜翅目毒液(HV)过敏患者有效,可显著改善患者的生活质量(QoL)。然而,viti诱导的耐受性可能在停止治疗后随着时间的推移而丧失,使患者面临再次蜇伤过敏反应的风险。材料和方法:为了研究VIT对维持HV耐受性的影响,我们评估了54例29年前接受VIT治疗的患者的自然病史,特别关注重新蜇伤及其后续病程。此外,我们分析了hiv特异性IgE、IgG和IgG4抗体滴度。最后,我们评估了VIT对各种心理社会方面的长期影响,如处理膜翅目昆虫暴露,日常生活活动,自信和个人环境。结果:29例(53.7%)受试者在停药后至少经历一次再刺痛,23例(79%)无全身反应。其中11人(37.9%)将急救药物作为安全措施。6人(21%)表现出耐受性丧失,出现过敏反应。不同患者的hiv特异性IgE、IgG4或IgG抗体浓度没有差异。在没有使用紧急药物的情况下耐受再次蜇伤的受试者,当膜翅目昆虫在周围时,他们的社会行为休闲活动受到的影响最小,或者对新的蜇伤感到焦虑。结论:VIT在大多数hv过敏患者中导致长期耐受性,然而,约1/5可能随着时间的推移失去保护,因此需要继续对VIT治疗的受试者进行随访,并为他们配备急救箱。值得注意的是,在不使用紧急药物的情况下耐受重新注射的人,静脉注射还会对自信心和幸福感产生持久而强烈的影响,这强调了只有在停止静脉注射成功后出现全身症状时才需要使用它们。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Long-term impact of hymenoptera venom immunotherapy on clinical course, immune parameters, and psychosocial aspects.

Long-term impact of hymenoptera venom immunotherapy on clinical course, immune parameters, and psychosocial aspects.

Long-term impact of hymenoptera venom immunotherapy on clinical course, immune parameters, and psychosocial aspects.

Long-term impact of hymenoptera venom immunotherapy on clinical course, immune parameters, and psychosocial aspects.

Background: Venom immunotherapy (VIT) is highly efficient in subjects suffering from IgE-mediated allergy to hymenoptera venom (HV), and VIT results in substantial improvement of quality of life (QoL). However, VIT-induced tolerance may be lost over time after cessation of treatment, putting patients at risk of re-sting anaphylaxis.

Materials and methods: To study the effect of VIT on maintenance of HV tolerance we evaluated the natural history of 54 patients who were treated with VIT up to 29 years ago, with a special focus on re-stings and their subsequent course. Furthermore, we analyzed HV-specific IgE, IgG, and IgG4 antibody titers. Finally, we assessed the long-term impact of VIT on various psychosocial aspects like dealing with hymenoptera exposures, daily life activities, self-assurance, and personal environment.

Results: 29 (53.7%) subjects experienced at least one re-sting after stopping VIT, with 23 (79%) showing no systemic reaction (SR). Eleven of these (37.9%) took emergency drugs as a safety measurement. Six individuals (21%) showed loss of tolerance experiencing an anaphylactic reaction. No difference in HV-specific IgE, IgG4, or IgG antibody concentrations was noticed among the different patients. Subjects who tolerated a re-sting without applying emergency drugs felt least affected in their social-behavioral leisure activities when hymenoptera were around or by anxiety for new stings.

Conclusion: VIT leads to long-term tolerance in the majority of HV-allergic patients, however, ~ 1/5 may lose protection over time, arguing for continued follow-up on VIT-treated subjects and keeping them equipped with an emergency kit. Notably, VIT also results in a lasting, strong impact on self-assurance and sense of well-being in individuals who tolerated a re-sting without employing emergency drugs, which emphasizes the need to use them only in case of systemic symptoms after stopping successful VIT.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信